Therapeutic effect of transurethral laser vaporization for benign prostatic hyperplasia(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2021年第9期
- Page:
- 1158-1161
- Research Field:
- 医学生物物理
- Publishing date:
Info
- Title:
- Therapeutic effect of transurethral laser vaporization for benign prostatic hyperplasia
- Author(s):
- LI Hongmei; WANG Xiyou; CHEN Anlong; LIU Cuilong
- Department of Urology Surgery, the Sixth Medical Center, Chinese PLA General Hospital, Beijing 100048, China
- Keywords:
- benign prostatic hyperplasia laser vaporization transurethral plasmakinetic prostatectomy
- PACS:
- R697.3
- DOI:
- 10.3969/j.issn.1005-202X.2021.09.020
- Abstract:
- Objective To investigate the therapeutic effect of laser vaporization for benign prostatic hyperplasia (BPH).
Methods A total of 62 BPH patients were grouped according to different treatment strategies. Transurethral plasmakinetic
prostatectomy (TUPKP) was adopted in control group, while transurethral 1 470 nm laser vaporization in study group. The
levels of hemoglobin and blood sodium before and after operation, perioperative indicators (postoperative durations of
bladder irrigation, indwelling catheter and hospital stay), IPSS, QOL, Qmax and PVR were compared between two groups.
Results The postoperative hemoglobin level in study group was significantly higher than that in control group (P<0.05), but
the difference in postoperative blood sodium level between two groups was trivial (P>0.05). Although the operation in study
group took longer than control group (P<0.05), the postoperative durations of bladder irrigation, indwelling catheter and
hospital stay in study group were shorter than those in control group (P<0.05). There was no significant difference in IPSS,
QOL, Qmax and PVR between two groups after treatment (P>0.05). The patients were followed-up for 3 months, and no shortterm
postoperative complication was found in study group, but secondary bleeding occurred in 1 case in control group.
Conclusion Both 1 470 nm laser vaporization and TUPKP for BPH can significantly alleviate the relevant lower urinary tract
symptoms, and significantly improve the quality of life of patients and the clinical efficacy is very similar. The operation
duration of transurethral 1 470 nm laser vaporization for BPH is relatively longer than TUPKP, but the former can make
postoperative recovery faster, and has a higher clinical safety.
Last Update: 2021-09-27